Semin Thromb Hemost 2009; 35(8): 814-819
DOI: 10.1055/s-0029-1245114
© Thieme Medical Publishers

Prophylaxis in Congenital Hemophilia with Inhibitors: The Role of Recombinant Activated Factor VII

Massimo Franchini1 , Franco Manzato2 , Gian Luca Salvagno3 , Martina Montagnana3 , Marco Zaffanello4 , Giuseppe Lippi5
  • 1Servizio di Immunoematologia e Medicina Trasfusionale, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero-Universitaria di Parma, Parma
  • 2Laboratorio di Patologia Clinica, Ospedale “Carlo Poma”, Mantova
  • 3Sezione di Chimica Clinica, Dipartimento di Scienze Biomediche e Morfologiche, Università di Verona, Verona
  • 4Dipartimento Materno-Infantile e di Biologia Genetica; Verona
  • 5Unità Operativa di Diagnostica Ematochimica, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero-Universitaria di Parma, Parma; Italy
Further Information

Publication History

Publication Date:
18 February 2010 (online)

Zoom Image

ABSTRACT

The development of inhibitors against therapeutically administered factors VIII or IX is actually the most challenging complication of hemophilia patients with inhibitors. The introduction of bypassing agents (i.e., activated prothrombin complex concentrates and recombinant activated factor VII [rFVIIa]) has dramatically improved the management of bleeding episodes in such patients. Over the last decade, there have been increasing reports on the ability of bypassing agents to prevent surgical, joint, or other bleeds in inhibitor patients. The published data on the use of rFVIIa as a prophylactic treatment in hemophilia patients with inhibitors are reviewed in this article.